Evidence map›Paper›PMID 27778067›Full record

ArticleRheumatology international2016

Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry.

M Cárdenas, S de la Fuente, M C Castro-Villegas, M Romero-Gómez, D Ruiz-Vílchez, J Calvo-Gutiérrez, A Escudero-Contreras, J R Del Prado, E Collantes-Estévez, P Font

Abstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

M CárdenasPharmacy Department, Reina Sofía Universitary Hospital, University of Córdoba, Córdoba, Spain. manuelj.cardenas.sspa@juntadeandalucia.es.ORCID http://orcid.org/0000-0003-0327-0420
S de la FuentePharmacy Department, Reina Sofía Universitary Hospital, University of Córdoba, Córdoba, Spain.
M C Castro-VillegasRheumatology Department, Reina Sofía Universitary Hospital, IMIBIC/University of Córdoba, Córdoba, Spain.
M Romero-GómezRheumatology Department, Reina Sofía Universitary Hospital, IMIBIC/University of Córdoba, Córdoba, Spain.
D Ruiz-VílchezRheumatology Department, Reina Sofía Universitary Hospital, IMIBIC/University of Córdoba, Córdoba, Spain.
J Calvo-GutiérrezRheumatology Department, Reina Sofía Universitary Hospital, IMIBIC/University of Córdoba, Córdoba, Spain.
A Escudero-ContrerasRheumatology Department, Reina Sofía Universitary Hospital, IMIBIC/University of Córdoba, Córdoba, Spain.
J R Del PradoPharmacy Department, Reina Sofía Universitary Hospital, University of Córdoba, Córdoba, Spain.
E Collantes-EstévezRheumatology Department, Reina Sofía Universitary Hospital, IMIBIC/University of Córdoba, Córdoba, Spain.
P FontRheumatology Department, Reina Sofía Universitary Hospital, IMIBIC/University of Córdoba, Córdoba, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To analyse the cost-effectiveness, in daily clinical practice, of the strategy of treating to the target of clinical remission (CR) in patients with established rheumatoid arthritis (RA), after 2 years of treatment with biological therapy. Adult patients with established RA were treated with biological therapy and followed up for 2 years by a multidisciplinary team responsible for their clinical management. Treatment effectiveness was evaluated by the DAS28 score. The direct costs incurred during this period were quantified from the perspective of the healthcare system. We calculated the cost-effectiveness of obtaining a DAS28 < 2.6, considered as CR. The study included 144 RA patients treated with biological therapies. After 2 years of treatment, 32.6% of patients achieved CR. The mean cost of achieving CR at 2 years was 79,681 ± 38,880 euros. The strategy of treatment to the target of CR is considered the most effective, but in actual clinical practice in patients with established RA, it has a high cost.

Indexed as

Cost-Benefit AnalysisAdultAntirheumatic AgentsArthritis, RheumatoidBiological ProductsDatabases, FactualFemaleHealth Care CostsHumansMaleMethotrexateMiddle AgedRemission InductionSeverity of Illness IndexSulfasalazineTreatment OutcomeAntirheumatic AgentsBiological ProductsMethotrexateSulfasalazineBiological drugsClinical remissionCost-effectivenessReal clinical practiceRheumatoid arthritisTreat to target

Identifiers

PMID27778067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.